Loading clinical trials...
Loading clinical trials...
This study is designed as a proof of concept of AIN457 in patients with psoriatic arthritis. The study will address the evaluation of the efficacy at 6 and up to 24 weeks after two doses of AIN457 10 ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT07486960 · Psoriatic Arthritis
NCT07536529 · Inflammatory Joint Diseases, Rheumatoid Arthritis (RA), and more
NCT07295509 · Psoriatic Arthritis
NCT07286058 · Psoriatic Arthritis
NCT06100744 · Juvenile Psoriatic Arthritis
Novartis Investigative Site
Berlin
Novartis Investigative Site
Hamburg
Novartis Investigative Site
Hamburg
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions